The data shown below were collected from the profiles of 164 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Estimates of benefits and harms of prophylactic use of aspirin in the general population
|
|---|---|
| Published in |
Annals of Oncology, August 2014
|
| DOI | 10.1093/annonc/mdu225 |
| Pubmed ID | |
| Authors |
J. Cuzick, M.A. Thorat, C. Bosetti, P.H. Brown, J. Burn, N.R. Cook, L.G. Ford, E.J. Jacobs, J.A. Jankowski, C. La Vecchia, M. Law, F. Meyskens, P.M. Rothwell, H.J. Senn, A. Umar |
| Abstract |
Accumulating evidence supports an effect of aspirin in reducing overall cancer incidence and mortality in the general population. We reviewed current data and assessed the benefits and harms of prophylactic use of aspirin in the general population. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 23 | 14% |
| United States | 22 | 13% |
| Spain | 7 | 4% |
| Canada | 4 | 2% |
| Switzerland | 3 | 2% |
| Netherlands | 2 | 1% |
| India | 2 | 1% |
| Australia | 2 | 1% |
| Greece | 2 | 1% |
| Other | 18 | 11% |
| Unknown | 79 | 48% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 106 | 65% |
| Practitioners (doctors, other healthcare professionals) | 31 | 19% |
| Scientists | 18 | 11% |
| Science communicators (journalists, bloggers, editors) | 9 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 324 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 4 | 1% |
| France | 2 | <1% |
| Germany | 1 | <1% |
| Netherlands | 1 | <1% |
| Australia | 1 | <1% |
| Egypt | 1 | <1% |
| Unknown | 314 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 56 | 17% |
| Student > Bachelor | 44 | 14% |
| Other | 31 | 10% |
| Student > Master | 31 | 10% |
| Student > Ph. D. Student | 30 | 9% |
| Other | 64 | 20% |
| Unknown | 68 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 132 | 41% |
| Agricultural and Biological Sciences | 31 | 10% |
| Biochemistry, Genetics and Molecular Biology | 23 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 5% |
| Nursing and Health Professions | 8 | 2% |
| Other | 35 | 11% |
| Unknown | 79 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 524. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 December 2023.
All research outputs
#51,421
of 26,588,548 outputs
Outputs from Annals of Oncology
#18
of 7,996 outputs
Outputs of similar age
#329
of 242,401 outputs
Outputs of similar age from Annals of Oncology
#1
of 141 outputs
Altmetric has tracked 26,588,548 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,996 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,401 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 141 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.